Semax side effects and risks

Reported side effects

• Nasal irritation: Mild irritation with prolonged use in Russian instructions; no rate given., mild (source)
• Abnormal EEG activity: Reported in some of 73 posthypoxic patients; event count and seizure rate unavailable., serious (source)
• Eye pain or burning: One FDA consumer report included hospitalization; causality and product quality unconfirmed., serious (source)
• Immune reactions to impurities: FDA identifies a potential risk; human incidence is unknown., serious (source)

Stop and get help if

• Trouble breathing, face or throat swelling, or collapse: Stop exposure and get emergency care now.
• Sudden weakness, facial droop, speech trouble or sudden vision loss: Call emergency services immediately; do not delay stroke care for a peptide.
• A seizure, loss of awareness or new severe confusion: Stop exposure and get emergency care.
• Persistent eye pain, burning or new visual symptoms: Stop exposure and seek urgent eye assessment.

Who should avoid it

• pregnant: Russian instructions contraindicate pregnancy; controlled pregnancy safety studies are absent.
• breastfeeding: Russian instructions contraindicate breastfeeding; infant exposure and safety are unknown.
• tryingToConceive: Precaution: reproductive safety and a preconception washout interval are not established.
• under18: Russian pediatric use does not establish safety of online preparations.
• other: Avoid after allergy to the peptide or formulation, including its preservatives.
• testedAthlete: 2026 status is unresolved for the exact substance and formulation; obtain an anti-doping ruling.
• kidneyDisease: No reliable dose-adjustment studies for kidney impairment were located.
• liverDisease: No reliable dose-adjustment studies for liver impairment were located.
• psychiatricCondition: Review symptoms and psychiatric medicines; the available trials do not cover every diagnosis or combination.
• other: Blocked or irritated nasal passages can make delivery unreliable; review persistent nose symptoms.
• seizureDisorder: Russian instructions contraindicate a seizure history; one clinical report described abnormal EEG activity.
• other: Russian instructions list acute psychiatric conditions and anxiety disorders as contraindications.
• bleedingDisorder: FDA flags a possible bleeding concern from limited clotting data; clinical risk is not quantified.
• activeCancer: Cancer safety is unstudied. Preclinical growth-factor effects do not establish safety in active cancer.
• surgeryPlanned: Review use before surgery because FDA raises a possible bleeding concern; no validated stopping interval exists.

Interactions

• Nasal decongestants: Russian instructions discourage local nasal vasoconstrictors; they may alter delivery.
• Anticoagulants and antiplatelet drugs: Possible added bleeding risk is a precaution from limited clotting evidence, not a proven clinical interaction.
• Prescription stimulants: Semax amplified amphetamine effects in rodents. Human interaction risk is unknown.
• Selank and modified nootropic peptides: No controlled human combination trial or interchangeable dose has been established.

Product quality risks

• Seized powders were identified as Semax and Selank by mass spectrometry; that study did not establish sterility or a market-wide contamination rate.
• FDA flags immune reactions from aggregation and peptide-related impurities. A nasal route does not remove quality risks.
• Unregulated preparations can contain the wrong amount, microbes or bacterial toxins. No representative assay survey of these two products was found.